DUL:ETR
Alnylam Pharmaceuticals, Inc.
202,20 €
arrow_upward
+0,65%(+1,30) 1D
14 հոկ, 17:35:58 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
200,10 €
High
202,20 €
Low
200,10 €
Mkt. cap
30,04 մլրդ
Avg. vol.
39,00
Volume
0,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 հզր
Open
200,10 €
High
202,20 €
Low
200,10 €
Mkt. cap
30,04 մլրդ
Avg. vol.
39,00
Volume
0,00
52-wk high
417,40 €
52-wk low
177,10 €
No. of employees
2 հզր
News stories
From web sources and news partners
Yahoo Finance
·
9 ժամ առաջ
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
BioSpace
·
20 ժամ առաջ
Alnylam bulls and bears fight it out after business-shaking guidance cut
The Globe and Mail
·
2 շաբաթ առաջ
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.